American Society of Clinical Oncology All rights reserved.

Size: px

Start display at page:

Brooke Armstrong
6 years ago
Views:

1 Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-EGFR Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

2 Introduction This PCO Update addresses recent evidence suggesting that RAS mutations in exons 2 (codons 12, 13), 3 (codons 59, 61), and 4 (codons 117, 146) of both KRAS and NRAS may be predictive of resistance to treatment with monoclonal antibodies (MoAb) (currently cetuximab and panitumumab) targeting the EGFR. Analysis was limited to systematic reviews with or without meta-analysis that assessed the addition of anti-egfr MoAbs to standard therapy (i.e. cytotoxic or best-supportive care) as this was the largest group of studies with sufficiently similar treatment comparisons.

3 PCO Methodology An ASCO provisional clinical opinion (PCO) offers timely clinical direction to oncologists following publication or presentation of potentially practice-changing data from major studies.

4 Statement of the Clinical Issue Results from Phase II and III clinical trials of the anti-egfr MoAbs cetuximab and panitumumab when used either as monotherapy or in combination with chemotherapy have shown that patients with metastatic colorectal cancer may benefit from these therapies and both agents are FDA-approved for treatment of metastatic colorectal cancer (mcrc). Stratified analyses of data from these trials by RAS mutational status no mutation detected or mutation detected indicated that patients whose tumors harbor KRAS or NRAS mutations in exon 2 (codons 12, 13), exon 3 (codons 59, 61) and exon 4 (codons 117, 146) are unlikely to derive benefit from treatment with anti-egfr monoclonal antibody therapy (currently cetuximab or panitumumab).

5 Target Population and Audience Target Population Individuals with metastatic colorectal cancer who are candidates for anti-egfr antibody therapy. Target Audience Medical professionals who treat individuals with metastatic colorectal cancer.

6 Updated ASCO Provisional Clinical Opinion RAS mutational testing of colorectal carcinoma tissue should be performed in a CLIA-certified laboratory for all patients who are being considered for anti-egfr monoclonal antibody therapy. Mutational analysis should include KRAS and NRAS codons 12, 13 of exon 2; 59, 61 of exon 3; and 117 and 146 of exon 4. The weight of current evidence indicates that anti-egfr monoclonal antibody therapy (currently cetuximab and panitumumab) should only be considered for treatment of people with mcrc who are identified as having tumors with no mutations detected after such extended RAS mutation analysis.

7 What s New and Different? In addition to testing for mutations in KRAS exon 2 (codons 12, 13) as recommended previously, before treatment with anti-egfr antibody therapy, people with metastatic colorectal cancer should have their tumor tested for mutations in: KRAS exon 3 (codons 59, 61) and exon 4 (codons 117, 146) NRAS exon 2 (codons 12, 13), exon 3 (codons 59, 61), and exon 4 (codons 117, 146)

8 Additional Resources More information is available at Patient information is available at

9 ASCO PCO Panel Members Member Carmen J. Allegra, co-chair Richard L. Schilsky, co-chair Stanley R. Hamilton Nancy Roach Alexander Hantel Affiliation University of Florida, Gainesville, FL American Society of Clinical Oncology, Alexandria, VA University of Texas MD Anderson Cancer Center, Houston, TX Fight Colorectal Cancer, Alexandria, VA Edward Cancer Center, Naperville, IL

10 Provisional Clinical Opinion Note ASCO s provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidence and literature available at the time they are written, and are intended to assist physicians in clinical decision-making and identify questions and settings for further research. Due to the rapid flow of scientific information in oncology, new evidence may have emerged since the time a PCO was submitted for publication. PCOs are not continually updated and may not reflect the most recent evidence. PCOs cannot account for individual variation among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine the best course of treatment for the patient. Accordingly, adherence to any PCO is voluntary, with the ultimate determination regarding its application to be made by the physician in light of each patient s individual circumstances. ASCO PCOs describe the use of procedures and therapies in clinical practice and cannot be assumed to apply to the use of these interventions in the context of clinical trials. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of ASCO s PCOs, or for any errors or omissions.

11 Disclaimer The Clinical Practice Guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist providers in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like must, must not, should, and should not indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an as is basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

If multiple KRAS mutation tests have been performed, refer to the most recent test results.

If multiple KRAS mutation tests have been performed, refer to the most recent test results. Measure #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy